EudraVigilance releases 2024 annual report for the European Parliament, the Council and the Commission
EudraVigilance, the European system for managing and analysing information on suspected adverse drug reaction reports, is the tool that the EMA and national competent authorities use to monitor the safety of all investigational and authorised medicines in the EU. It complements the routine benefit-risk re-evaluation of authorised medicines performed by the EMA’s Pharmacovigilance Risk Assessment Committee through the assessment of periodic safety update reports and risk management plans. Please find the annual EudraVigilance report for 2024 here.
News reported on the 2nd of April 2025 in Catapult’s regulatory round-up, read the entire report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). EudraVigilance releases 2024 annual report for the European Parliament, the Council and the Commission. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/13yjy





